Estcourt L J
NHS Blood and Transplant, Oxford, UK; Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Transfus Med. 2014 Oct;24(5):260-8. doi: 10.1111/tme.12155.
Platelet transfusions are used in clinical practice to prevent and treat haemorrhage in thrombocytopenic patients or patients with severe platelet dysfunction. In the UK, and abroad there has been a recent rise in platelet component demand. The three largest patient groups that use platelet components are patients with haematological malignancies (up to 67%), patients receiving cardiac surgery (up to 10%) and patients receiving intensive care (up to 8%). This review has explored some of the factors that may explain this recent trend within these three main groups. These factors include a rise in the general population, an ageing population, an increase in the incidence and prevalence of haematological malignancies, and changes in the management of patients with haematological malignancies. However, the only data available that can be correlated directly with national component data are the size of the total population. There is no evidence to support the premise that use of platelet components in patients receiving cardiac surgery or intensive care treatment is rising over and above the general rise in the population, but the data are sparse.
在临床实践中，血小板输注用于预防和治疗血小板减少症患者或严重血小板功能障碍患者的出血。在英国及其他国家，近期血小板成分的需求有所增加。使用血小板成分的三大患者群体是血液系统恶性肿瘤患者（高达67%）、接受心脏手术的患者（高达10%）和接受重症监护的患者（高达8%）。本综述探讨了一些可能解释这三大主要群体近期这一趋势的因素。这些因素包括总人口增加、人口老龄化、血液系统恶性肿瘤的发病率和患病率上升，以及血液系统恶性肿瘤患者管理方式的改变。然而，唯一可直接与全国成分数据相关的现有数据是总人口规模。没有证据支持接受心脏手术或重症监护治疗的患者使用血小板成分的情况超出总人口的普遍增长，但相关数据较少。
